Pharmaceuticals Malaysia

Malaysia GLP-1 Receptor Agonists Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Malaysia GLP-1 Receptor Agonists Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route of Administration, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Malaysia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $78.5 Mn Placeholder estimate
Estimate 2025 $92.6 Mn 0.2% of the global market
Projected 2034 $407.5 Mn 340.2% Adds $314.9 Mn over 9 forecast years
CAGR 2025–2034 17.9% Faster than 81% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Malaysia is 0.18% of the global market.
  • In APAC, the largest is China at $3.75 Bn.
  • Fastest growing: India at 20.6% a year.
  • Malaysia ranks 8th of 10 by size in APAC.

Market size projection

Malaysia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$314.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
GLP-1 Receptor Agonists Market market size by year, Malaysia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $78.5 Mn — —
2025 (base) $92.6 Mn +$14.1 Mn —
2026 (forecast) $109.1 Mn +$16.6 Mn +17.9%
2027 (forecast) $128.7 Mn +$19.5 Mn +39%
2028 (forecast) $151.7 Mn +$23.0 Mn +63.9%
2029 (forecast) $178.9 Mn +$27.2 Mn +93.2%
2030 (forecast) $210.9 Mn +$32.0 Mn +127.8%
2031 (forecast) $248.6 Mn +$37.8 Mn +168.6%
2032 (forecast) $293.2 Mn +$44.5 Mn +216.7%
2033 (forecast) $345.6 Mn +$52.5 Mn +273.3%
2034 (forecast) $407.5 Mn +$61.9 Mn +340.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $52.46 Bn
  2. North America $27.54 Bn
  3. US $22.68 Bn
  4. Europe $10.02 Bn
  5. APAC $10.15 Bn
  6. Canada $4.26 Bn
  7. China $3.75 Bn
  8. Japan $3.63 Bn
  9. Latin America $2.72 Bn
  10. Middle East $2.30 Bn
  11. Germany $2.03 Bn
  12. Brazil $1.50 Bn
  13. France $1.38 Bn
  14. Italy $1.37 Bn
  15. UK $1.21 Bn
  16. India $1.01 Bn
  17. Saudi Arabia $976.3 Mn
  18. Ecuador $905.6 Mn
  19. Spain $878.1 Mn
  20. Africa $770.4 Mn
  21. Mexico $719.6 Mn
  22. Australia $736.7 Mn
  23. New Zealand $599.4 Mn
  24. Russia $527.6 Mn
  25. South Africa $346.9 Mn
  26. UAE $244.5 Mn
  27. Egypt $133.9 Mn
  28. Philippines $102.8 Mn
  29. Hong Kong $96.0 Mn
  30. Malaysia (this report) $92.6 Mn
  31. Singapore $71.3 Mn
  32. Thailand $59.5 Mn
  33. Kenya $33.8 Mn

Report snapshot

Malaysia GLP-1 Receptor Agonists Market Analysis at a glance
Market size, 2025$92.6 Mn placeholder estimate
Forecast, 2034$407.5 Mn placeholder estimate
Growth (CAGR), 2025–203417.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, route of administration, application and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Sanofi, Amgen Inc. and 1 more (see all)
Regulator in MalaysiaNPRASource: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Malaysia GLP-1 Receptor Agonists Market Analysis Executive Summary

GLP-1 receptor agonists are medicines that mimic a gut hormone to lower blood sugar, slow digestion and reduce appetite. They are used to treat type 2 diabetes and obesity.

Key segments of the GLP-1 Receptor Agonists market include drug (Semaglutide, Tirzepatide and Liraglutide), route of administration (Injectable and Oral) and application (Type 2 Diabetes, Obesity and Cardiovascular Risk Reduction).

Bar chart: Malaysia GLP-1 Receptor Agonists market size, 2024–2034, placeholder estimates. $78.5 Mn in 2024, $92.6 Mn in 2025 and $407.5 Mn in 2034, 17.9% CAGR.
Malaysia GLP-1 Receptor Agonists market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Malaysia GLP-1 Receptor Agonists Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the GLP-1 Receptor Agonists market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the GLP-1 Receptor Agonists market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the GLP-1 Receptor Agonists market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for GLP-1 Receptor Agonists Market in Malaysia

The GLP-1 Receptor Agonists market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for GLP-1 Receptor Agonists Market in Malaysia

GLP-1 Receptor Agonists in Malaysia: rules, payment and health figures

Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA).⁠[1] Public clinics and hospitals run by the Ministry of Health give heavily subsidised care.⁠[2] Obesity (adults): 23.3% of adults in 2024, the latest WHO figure for Malaysia.⁠[3]

[1] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[2] Ministry of Health Malaysia. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for GLP-1 Receptor Agonists. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in GLP-1 Receptor Agonists right now, from free public sources.

Latest research 4,726 papers since 2021 (worldwide)

  1. GLP-1 Receptor Agonist Use and Risk of Pain-Related Medical Encounters Among Patients with Comorbid Type 2 Diabetes and Opioid Use Disorder: A Target Trial Emulation Study. The journal of pain, 2026
  2. Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults - United States, 2025. MMWR. Morbidity and mortality weekly report, 2026
  3. Will sarcopenia preventative pharmacology ensure the long-term success of GLP-1-derived therapies? Expert opinion on pharmacotherapy, 2026
  4. GLP-1 dose escalation and disputed ignition interlock alcohol results: Case report. The Medico-legal journal, 2026
  5. AI-enabled drug repurposing in Alzheimer's disease: from computational nomination to pharmacological proof. Frontiers in pharmacology, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

GLP-1 Receptor Agonists in context

Malaysia compared

  • Obesity (adults): 23.3% of adults (2024). World: 16.2% of adults (2024). 4th highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 450 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 15 countries we cover in APAC.[2]
  • Doctors: 2.34 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 6th highest of the 15 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the GLP-1 Receptor Agonists market in Malaysia?
Placeholder estimate: about $92.6 Mn in 2025, rising to about $407.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the GLP-1 Receptor Agonists market in Malaysia growing?
Placeholder estimate: about 17.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the GLP-1 Receptor Agonists market report cover?
The report splits the market by drug (Semaglutide, Tirzepatide, Liraglutide, Dulaglutide and more), route of administration (Injectable, Oral), application (Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the GLP-1 Receptor Agonists market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Sanofi, Amgen Inc. and Pfizer Inc..
What is driving the GLP-1 Receptor Agonists market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the GLP-1 Receptor Agonists market.
Who regulates GLP-1 Receptor Agonists in Malaysia?
Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA). Source: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in Malaysia?
Public clinics and hospitals run by the Ministry of Health give heavily subsidised care. Source: Ministry of Health Malaysia. Checked 14 Nov 2026.
What does WHO report for Malaysia?
Obesity (adults): 23.3% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.
How many people in Malaysia are 65 or older?
8.0% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
How much research is published on GLP-1 Receptor Agonists?
PubMed lists 4,726 papers on GLP-1 Receptor Agonists added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about GLP-1 Receptor Agonists in Malaysia? Our analysts can size it for your plan. Talk to us See the public data Obesity (adults) for every country, free. Open the Public Health Dashboard

From our blog

Weight Management Supplements in the GLP-1 Era2.6 billion adults are overweight. GLP-1 medicines are changing weight care, while most supplements lack… Wound Care: Advanced Dressings for Faster HealingNearly 15% of US Medicare beneficiaries, 8.2 million people, had a wound or wound infection in one year… Snoring and Sleep Apnoea Devices: Sleeping BetterAn estimated 936 million adults have obstructive sleep apnoea, and most are undiagnosed. CPAP machines, oral…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Malaysia

See all
Same topic, other categories

Related on obesity and diabetes

See the topic